IP Library › Granted Patent US 11,572,388
Granted Patent B2
US 11,572,388 · App. 15/929,737 · Granted Feb 7, 2023

Chimeric polypeptides and uses thereof

Inventors: Jed J. W. Wiltzius (Winchester, MA); Stuart A. Sievers (Santa Monica, CA)
Assignee: Kite Pharma, Inc.
C07K14/003A61K39/0011A61K39/001112A61K47/65A61P35/02C07K4/00C07K7/06C07K7/08C07K16/2803C07K16/44C12N15/62C12N15/85A61K2039/5156A61K2039/5158C07K2317/32C07K2317/34C07K2317/622C07K2319/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,572,388
App. No.
15/929,737
Granted
Feb 7, 2023
Kind
B2
Abstract

The invention provides novel peptides (e.g., linkers) and polypeptide compositions comprising the linkers (e.g., fusion proteins) and methods of using the polypeptide compositions. Peptides (e.g., linkers) are useful as tags and for engineering fusion proteins (e.g., antigen binding molecules, scFv). Polypeptide linkers described herein facilitate flexibility of linked peptides allowing for proper folding, conformation and reduced immunogenicity.

Claims (12)

1. A fusion protein comprising:

a first polypeptide and a second polypeptide covalently linked by a peptide comprising a consensus sequence GKPGSGZ (SEQ ID NO: 33), wherein the peptide is 7-17 amino acids in length;

wherein the peptide is not GSTSGSGKPGSGEGSTKG (SEQ ID NO: 1), GSGKPGSGEG (SEQ ID NO: 13), GKPGSGEG (SEQ ID NO: 14), or SGKPGSGE (SEQ ID NO: 15),

wherein the peptide is selected from the group consisting of GKPGSGG (SEQ ID NO: 6), GSGKPGSGEGG (SEQ ID NO: 31), GGGSGKPGSGEGGGS (SEQ ID NO: 7), GGGSGKPGSGEGGGGS (SEQ ID NO: 8), GGGGSGKPGSGGGGS (SEQ ID NO: 9), GGGGSGKPGSGEGGS (SEQ ID NO: 10), GGGGSGKPGSGEGGGS (SEQ ID NO: 11), GGGGSGKPGSGEGGGGS (SEQ ID NO: 12), and STSGSGKPGSGEGST (SEQ ID NO: 17),

wherein the fusion protein is a CD19 specific scFv fusion protein comprising a light chain variable domain and a heavy chain variable domain, and

wherein the first polypeptide comprises the light chain variable region and the second polypeptide comprises the heavy chain variable domain.

2. A polynucleotide encoding any one of the peptide according to claim 1 .

3. A polynucleotide encoding the fusion protein of claim 1 .

4. An expression vector comprising the polynucleotide of claim 3 .

5. A recombinant cell comprising the polynucleotide of claim 3 .

6. The recombinant cell of claim 5 , wherein the cell is an immune cell.

7. The immune cell of claim 6 , wherein the immune cell is a T cell, NK cell, or a stem cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2020
From: SIEVERS, STUART A.; WILTZIUS, JED J.W.
To: KITE PHARMA, INC.
Reel/Frame 052968/0019 →
Continuity (3)
Continuation 16138331 · Sep 21, 2018
Provisional Application 62562223 · Sep 22, 2017
Related Publication 20200399320A1 · Dec 24, 2020
Cited By (1)
US 12,404,305